Context Therapeutics doses first patient in CT-202 Phase 1 trial

September 9, 2026 7:30 AM

Context Therapeutics Inc. (Nasdaq: CNTX) announced that the first patient has been dosed in a Phase 1 clinical trial of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found